News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk Shelley Wood March 08, 2023
News Conference News ACC 2023 Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT Yael L. Maxwell March 07, 2023
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
Presentation ACC 2018 CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes Presenter: Brendan M. Everett March 12, 2018
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017